



Amneal – Recall of ranitidine

- On January 10, 2020, [Amneal announced](#) a voluntary, consumer-level recall of prescription [ranitidine](#) tablets because of the potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the FDA.
 - This is an update to the recall that was announced by Amneal in November 2019. Amneal has added an additional NDC number and lot numbers to the recall.
- NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
- Refer to the announcement for a list of recalled NDCs and lot numbers.
- Prescription ranitidine is used as a short-term treatment for active duodenal ulcers, maintenance therapy for duodenal ulcer patients, treatment of pathological hypersecretory conditions, short-term treatment of active, benign gastric ulcers, maintenance therapy for gastric ulcers, treatment of gastroesophageal reflux disease, and treatment of endoscopically diagnosed erosive esophagitis.
- Patients taking prescription ranitidine who wish to stop should talk to their healthcare provider about other treatment options. Multiple drugs are approved for the same or similar uses as ranitidine.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled ranitidine.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- The FDA continues to evaluate the safety of ranitidine and will provide more information as it becomes available. Updates can be found [here](#).
- Contact Stericycle (appointed company for Amneal) at **1-866-918-8786** for further information regarding this recall.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.